Familial Amyloid Polyneuropathy Industry Growth Expected to Reach $2.25 Billion by 2029 at a CAGR of 8.1% | Segmentation and Growth Opportunities
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Familial Amyloid Polyneuropathy Market Growth in 2025?
In recent times, the market for familial amyloid polyneuropathy has experienced substantial growth. Predictions suggest that the market, valued at $1.52 billion in 2024, will increase to $1.65 billion in 2025 with an impressive compound annual growth rate (CAGR) of 8.4%. Factors contributing to this growth during the historic period include a heightened prevalence of familial amyloid polyneuropathy, increased awareness and identification rates due to enhanced genetic testing, a rising trend in the adoption of advanced therapeutic alternatives and targeted treatments, an escalating investment in the study and development of therapies for amyloidosis, along with a growing aging population prone to amyloid-related neuropathies.
What Is the Forecast for the Familial Amyloid Polyneuropathy Market Size Through 2029?
The market for familial amyloid polyneuropathy is predicted to witness robust expansion in the upcoming years, with a projected size of $2.25 billion by 2029 and a compound annual growth rate (CAGR) of 8.1%. This surge in the forecast period is likely as a result of numerous factors including intensified government actions and funding for the treatment of rare diseases, a surge in clinical trials that study innovative treatments, a rise in patient advocacy and support groups that demand superior therapies, enhanced access to healthcare facilities in developing markets, and an increased availability of sophisticated diagnostic instruments. Trends to look out for during the forecast period encompass advancements in genetic sequencing technology, the incorporation of personalized medicine, technological developments in identifying biomarkers, progress in drug delivery methods, and the inclusion of digital healthcare tools and telemedicine.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24532&type=smp
What are the Key Market Players in Familial Amyloid Polyneuropathy Market and How They’re Evolving?
Major companies operating in the familial amyloid polyneuropathy market are Pfizer Inc., AstraZeneca plc, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., NYU Langone Hospitals, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Mount Sinai Medical Center, PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Mayo Foundation for Medical Education and Research, Arcturus Therapeutics Inc., Prothena Corporation plc, Precision BioSciences Inc., Intellia Therapeutics Inc., Creative Biolabs, Stanford Health Care, Attralus Inc., Duke University Health System, YolTech Therapeutics.
What Are the Primary Growth Drivers in the Familial Amyloid Polyneuropathy Market?
The heightened attention on gene therapy is predicted to drive the advancement of the familial amyloid polyneuropathy market in the future. Gene therapy, which involves modifying or replacing defective genes to treat the root cause of illnesses, is gaining traction as it targets faulty genes for lasting or permanent cures, instead of just relieving symptoms. In the case of familial amyloid polyneuropathy, gene therapy is centered on correcting or silencing the problematic transthyretin (TTR) gene, inhibiting detrimental amyloid protein formation, which helps minimize amyloid deposits, decelerate the progress of the disease, and maintain nerve function. For instance, data from the American Society of Gene & Cell Therapy (ASGCT), a professional society in the US, and Citeline, a US-based provider of drug and device information, indicates that in July 2023, there were 247 gene therapies in Phase II at the close of the first quarter, a number that increased by 5% to 260 by the end of the second quarter. Hence, the escalating emphasis on gene therapy is fueling the growth of the familial amyloid polyneuropathy market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24532&type=smp
What Are the Leading Segments in the Global Familial Amyloid Polyneuropathy Industry?
The familial amyloid polyneuropathy market covered in this report is segmented –
1) By Treatment: Medication, Gene Therapy, Supportive Care, Pain Management, Symptomatic Treatment
2) By Diagnosis: Genetic Testing, Biopsy, Imaging, Other Diagnosis
3) By Patient Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies, Direct Sales
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Medication: Transthyretin (TTR) Stabilizers, Transthyretin (TTR) Gene Silencers, Tafamidis, Diflunisal, Patisiran
2) By Gene Therapy: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9-Based Therapy, RNA Interference (RNAi) Therapy, Antisense Oligonucleotides (ASO) Therapy
3) By Supportive Care: Physical Therapy, Occupational Therapy, Nutritional Support, Psychological Counseling
4) By Pain Management: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Opioids, Antidepressants, Anticonvulsants
5) By Symptomatic Treatment: Gastrointestinal Symptom Management, Cardiovascular Symptom Management, Autonomic Dysfunction Management, Orthostatic Hypotension Treatment
What Are the Key Market Trends in the Familial Amyloid Polyneuropathy Industry?
Leading firms in the familial amyloid polyneuropathy market are diligently working on the creation of advanced treatment methodologies, namely RNA interference (RNAi) therapeutics, in a bid to slow disease progression and enhance patient experience. RNA interference therapeutics are cutting-edge treatment options that mute disease-triggering genes by aiming their messenger RNA (mRNA), consequently halting the formation of harmful proteins and tackling genetic diseases right at their root. For instance, in March 2025, Alnylam Pharmaceuticals, a biopharmaceutical enterprise based in the US, introduced AMVUTTRA (vutrisiran) – an FDA-approved treatment for cardiomyopathy triggered by wild-type or inherited transthyretin-mediated amyloidosis (ATTR-CM) in adults. It is given in the form of four subcutaneous doses each year, designed to treat both ATTR-CM and the polyneuropathy related to inherited transthyretin-mediated amyloidosis (hATTR-PN). By curbing the formation of transthyretin (TTR) protein, which is fundamental to the disease, the drug considerably reduces instances of cardiovascular mortality, hospitalizations, and urgent heart failure visits, as seen in the results from the HELIOS-B Phase 3 clinical trial.
Access The Full Report Here:
What Is the Regional Outlook for the Familial Amyloid Polyneuropathy Market?
North America was the largest region in the familial amyloid polyneuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the familial amyloid polyneuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24532
This Report Delivers Insight On:
1. How big is the familial amyloid polyneuropathy market, and how is it changing globally?
2. Who are the major companies in the familial amyloid polyneuropathy market, and how are they performing?
3. What are the key opportunities and risks in the familial amyloid polyneuropathy market right now?
4. Which products or customer segments are growing the most in the familial amyloid polyneuropathy market?
5. What factors are helping or slowing down the growth of the familial amyloid polyneuropathy market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
